Theravance Biopharma Inc (TBPH) Company Sales Revenue

Corporate emblem and logo of Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma (TBPH) is monetizing the success of Yupelri in partnership with Viatris to develop its own molecules. The company's commercial revenue, where the value of 0.10 serves as the current metric, confirms the brand's high authority in respiratory therapy. The financial model relies on extracting profit from a mature asset portfolio without a sharp increase in research expenditures.

TBPH: Theravance Corp Revenue and Sales Volume 07/04/2022 - 10/10/2026

Analytical breakdowns for Theravance Biopharma

- market price and analyst price targets:
Summary company analysis:TBPH, Theravance Biopharma, Inc.
Original product of Theravance Biopharma Inc

For Theravance Biopharma (TBPH), revenue dynamics from product sales reflect the effectiveness of commercializing treatments for respiratory pathologies. The 0.10 metric is calculated as the aggregate volume of daily inflows, which allows for the filtering of market noise to identify the true sales trend. This metric measures real market expansion amidst fierce competition in the COPD segment. The stability of this trajectory confirms the viability of partnerships with major pharma behemoths. Sharp deviations on the chart signal the expiration of patent protection for key technologies.

Competing companies

HLN: Company Sales Revenue|Company Revenue Kenvue (KVUE)|VRNA (Verona Pharma Corp) - Company Sales Revenue|Company Revenue Jyong Biotech MENS|Ligand Pharma - Company Revenue|AMRX - Company Revenue|Company Total Revenue perrigo.com|ALVO (Alvotech SA) - Company Sales|Company Total Sales Volume Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Revenue and Sales Volume|ANIP: Company Sales Revenue|Company Revenue Afrezza (MNKD)|Revenue and Sales Volume amphastar.com (AMPH)|Revenue and Sales Volume PCRX (pacira.com)|Company Sales Revenue SPRY|Aquestive Corp - Revenue and Sales Volume|scpharmaceuticals.com (SCPH) - Company Sales|TECX: Revenue and Sales Volume|Tonix Pharmaceuticals - Company Sales Revenue|Company Sales SXTC|EPRX: Company Sales Revenue|Company Sales BHST (BioHarvest Sciences Inc.)|Company Gross Revenue Invizyne|Company Revenue Oramed Pharmaceuticals ORMP|Company Sales Revenue ENTX|HYFT - Company Revenue|Company Sales Revenue ABVC (ABVC BioPharma Inc.)|CPIX: Revenue and Sales Volume|Quantum BioPharma Limited - Company Sales Revenue|FGEN (FibroGen Corp) - Revenue and Sales Volume|Revenue and Sales Volume Telomir Pharmaceuticals|Revenue and Sales Volume RANI|SNYR (Synergy CHC Corp.) - Company Sales Revenue|Revenue and Sales Volume RLYB (Rallybio Corp)|LEXX: Company Sales Volume|PULM - Company Revenue|PTHL: Company Revenue|APM (aptorumgroup.com) - Company Sales|Lyra Therapeutics - Company Sales Revenue|Company Revenue Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Company Gross Revenue|Revenue and Sales Volume YCBD|PRFX: Company Annual Revenue|Company Revenue altamiratherapeutics.com CYTO|Revenue and Sales Volume Lipella Pharmaceuticals Inc LIPO|OPTN - Company Revenue|Company Gross Revenue Pieris Pharma PIRS|Procaps Group SA (PROC) - Company Revenue|Company Annual Revenue PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding) - Revenue and Sales Volume|SLRN: Company Sales Revenue|Revenue and Sales Volume TFFP